?VIROLOGY, IMMUNOLOGY & MICROBIOLOGY (VIM) CORE The broad, long-term objectives of the Virology, Immunology & Microbiology (VIM) Core are to provide laboratory support for HIV/AIDS-related basic and clinical HIV research to the UNC CFAR community.
The specific aims i nclude: (1) provide access to a diverse array of cost-effective services, (2) develop and evaluate new technologies applicable to research by CFAR investigators, (3) support of CFAR initiatives and collaborative research, (4) promote synergy between UNC CFAR Cores, UNC CFAR SWGs, and other CFARs, (5) provide mentoring, training, education, and outreach in the areas of virology, immunology, and microbiology, and (6) engage in evaluation and strategic planning. To achieve these aims, the VIM Core collaborates with UNC CFAR investigators to provide the services, specimens, equipment, or training needed by the investigators to achieve their research goals. The Core contributes to grant writing, design of experiments, and write-up of results. The services offered include specimen processing for clinical trials, provision of specimens from HIV-positive and HIV-negative individuals, viral quantitation, flow cytometry, measurement of antibodies and cytokines, and diagnostics for HIV and other sexually transmitted infections. New assays are developed in response to investigator requests and priority research areas for the CFAR. Management and strategic planning of the Core will be guided by consultation with the Core Directors, surveys of the CFAR membership, an Internal Advisory Board, an External Advisory Board, and through discussions at CFAR retreats.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI050410-19
Application #
9117226
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
19
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Muessig, Kathryn E; Knudtson, Kelly A; Soni, Karina et al. (2018) ""I DIDN'T TELL YOU SOONER BECAUSE I DIDN'T KNOW HOW TO HANDLE IT MYSELF."" DEVELOPING A VIRTUAL REALITY PROGRAM TO SUPPORT HIV-STATUS DISCLOSURE DECISIONS. Digit Cult Educ 10:22-48
Bradley, Todd; Ferrari, Guido; Haynes, Barton F et al. (2018) Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep 25:107-117.e3
Adimora, Adaora A; Ramirez, Catalina; Benning, Lorie et al. (2018) Cohort Profile: The Women's Interagency HIV Study (WIHS). Int J Epidemiol 47:393-394i
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Ong, Jason J; Wei, Chongyi; Pan, Stephen et al. (2018) Individuals have the right to avoid sex with partners unwilling to test for HIV but do not have a right to force them to test for HIV. J Acquir Immune Defic Syndr :
Qin, Yilu; Han, Larry; Babbitt, Andrew et al. (2018) Experiences using and organizing HIV self-testing. AIDS 32:371-381
Hightow-Weidman, Lisa B; Muessig, Kathryn; Rosenberg, Eli et al. (2018) University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development. JMIR Res Protoc 7:e10365
Garrett, Katy L; Chen, Jingxian; Maas, Brian M et al. (2018) A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. J Pharmacol Exp Ther 367:245-251
Henderson, Gail E; Peay, Holly L; Kroon, Eugene et al. (2018) Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics 44:270-276
Lancaster, Kathryn E; Hoffman, Irving F; Hanscom, Brett et al. (2018) Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis. J Int AIDS Soc 21:e25195

Showing the most recent 10 out of 1688 publications